Últimas noticias sobre Liquidia (NASDAQ:LQDA) Bolsa

Liquidia

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Liquidia Corp

Elevance Health's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) short percent of float has fallen 23.78% since its last report. The company recently reported that it has 2.48 million shares sold short, which is 1.09% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.56 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Elevance Health Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742402717_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Elevance Health has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Elevance Health's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Elevance Health's peer group average for short interest as a percentage of float is 5.09%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

How Do Investors Really Feel About Elevance Health?

Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) has outperformed the market over the past 5 years by 16.87% on an annualized basis producing an average annual return of 35.26%. Currently, Spotify Technology has a market capitalization of $120.20 billion. 
Buying $1000 In SPOT: If an investor had bought $1000 of SPOT stock 5 years ago, it would be worth $4,968.52 today based on a price of $587.18 for SPOT at the time of writing.
<h3>Spotify Technology's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742402713_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

SPOT

$1000 Invested In Spotify Technology 5 Years Ago Would Be Worth This Much Today

<figure class="wp-block-image size-large"><img decoding="async" src="https://thearorareport.com/wp-content/uploads/2025/03/2025-03-19_08h15_02.png" alt="" /></figure>
To gain an edge, this is what you need to know today.
<h4 class="wp-block-heading">Dot Plot And Balance Sheet</h4>
Please <a href="https://thearorareport.com/chart-analysis-stock-market-ai-agents-robots-nvidia-turkey-president-nvda-mc-03192025">click here</a> for an enlarged chart of NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>).
Note the following:
<ul>
<li>This article is about the big picture, not an individual stock.&nbsp; The chart of NVDA stock is being used to illustrate the point.</li>
<li>The chart shows that after a much anticipated keynote speech by Nvidia's CEO Jensen Huang, NVDA stock pulled back to the top band of the mini support zone.</li>
<li>The chart shows aggressive buying ahead of Huang's speech in anticipation of NVDA stock going higher.</li>
<li>The chart shows the momo crowd's expectations were not met.&nbsp; Those in the momo crowd who primarily buy call options are now sitting on large losses.</li>
<li>Huang's speech was excellent.&nbsp; Here are the key points from The Arora Report's analysis:
<ul>
<li>Nvidia is doing excellent as a company.&nbsp; There is a disconnect between NVDA stock price and Nvidia as a company.</li>
<li>The biggest market of all will be the market for robots.&nbsp; Nvidia is well positioned to provide AI intelligence and systems for robots.</li>
<li>Human-like AI agents are at the cusp of widespread adoption.&nbsp; These agents are based on reasoning models.&nbsp; Reasoning models need significantly more compute than regular models.&nbsp; AI agents will drive demand for Nvidia's chips.</li>
<li>Nvidia is moving into autonomous driving.&nbsp; Nvidia announced a deal with General Motors Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>).</li>
<li>Nvidia is widening its lead over competitors.</li>
<li>Nvidia is strengthening its moat.</li>
</ul>
</li>
<li>Here is the question everyone is asking: In spite of so many positives, why did NVDA stock not rocket up?  </li>
<li>We have <a href="https://www.benzinga.com/markets/equities/25/03/44380831/the-opposite-of-what-wall-street-told-you-about-stocks-has-happened-key-nvidia-event-ahead">previously shared</a> with readers that the problem NVDA stock has is over-ownership.</li>
<li>Nvidia illustrates the beauty of the highly refined, multilayer methodology followed by members of The Arora Report.
<ul>
<li>The original core position in NVDA stock is long from $12.55 and most of the position is still being held.&nbsp; This illustrates the power of the ZYX Change Method to buy a stock when it is in <a href="https://thearorareport.com/ppp-long-trade-ppp">stage one</a>.</li>
<li>The fact that most of the position is still being held, resulting in major gains, shows the foresight that comes from decades of experience.</li>
<li>Along the way, there have been successful, shorter term, trade around positions.</li>
<li>The core position is appropriately hedged to preserve the gains.</li>
</ul>
</li>
<li>The Fed will announce its rate decision at 2pm ET, followed by Chair Powell's press conference at 2:30pm ET.  The Fed is expected to leave rates unchanged.  We will be carefully analyzing the following:
<ul>
<li>The dot plot</li>
<li>The Fed's balance sheet, especially regarding QT</li>
<li>How Powell straddles the uncertainty caused by tariffs</li>
<li>The Fed's take on rising consumer inflation expectations.&nbsp; Rising consumer inflation expectations are the last thing the Fed wants to see.</li>
</ul>
</li>
<li>The momo crowd's historical pattern is to buy ahead of the Fed meeting on hopium.&nbsp; This morning is no different.&nbsp; The momo crowd is buying stocks in the early trade hoping the Fed will help the market run up.</li>
</ul>
<h4 class="wp-block-heading">Japan</h4>
Prudent investors keep a close eye on the Bank of Japan (BOJ) due to the impact of the carry trade on stock markets across the globe including the U.S. stock market, particularly tech stocks.
BOJ has been in the mode of raising interest rates.&nbsp; However, after its latest meeting, the BOJ left rates unchanged.&nbsp; This has stopped the rise of the yen.
The primary reason BOJ did not raise interest rates appears to be the potential fallout from U.S. tariffs.&nbsp;&nbsp;
<h4 class="wp-block-heading">Turkey</h4>
Turkey has detained the mayor of Istanbul Ekrem Imamoglu.&nbsp; He is the main rival to Turkish President Erdogan.&nbsp; The opposition is calling this "a coup against our next president."&nbsp; Before this development, Turkey had a lot going for it.
<ul>
<li>Turkey will benefit from increased spending in Europe.</li>
<li>Turkey will benefit from thawing relations between the U.S. and Russia.</li>
<li>Turkey has lately engaged in investor friendly policies.&nbsp; As a result, there is a lot of room for the Turkish market to run.</li>
</ul>
The detention of Erdogan's main rival has raised concerns about political upheaval.&nbsp; The Turkish lira crashed as much as 12% on the news.
A big dip in Turkey will likely be a buying opportunity. &nbsp;Turkey has been covered continuously in The Arora Reoprt&#8217;s ZYX Emerging for 18 years.
<h4 class="wp-block-heading">Magnificent Seven Money Flows</h4>
In the early trade, money flows are positive in Apple Inc (AAPL), Amazon.com, Inc. (AMZN), Alphabet Inc Class C (GOOG), Meta Platforms Inc (META), Microsoft Corp (MSFT), and Tesla Inc (TSLA).
In the early trade, money flows are positive in SPDR S&amp;P 500 ETF Trust :SPY) and Invesco QQQ Trust Series 1 (QQQ).
<h4 class="wp-block-heading">Momo Crowd And Smart Money In Stocks</h4>
Investors can gain an edge by knowing money flows in SPY and QQQ.&nbsp; Investors can get a bigger edge by knowing when smart money is buying stocks, gold, and oil.&nbsp; The most popular ETF for gold is SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>).&nbsp; The most popular ETF for silver is iShares Silver Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLV#NYSE">SLV</a>).&nbsp; The most popular ETF for oil is United States Oil ETF (ASCA:USO).
<h4 class="wp-block-heading">Bitcoin</h4>
Bitcoin is range bound.
<h4 class="wp-block-heading">Protection Band And What To Do Now</h4>
It is important for investors to look ahead and not in the rearview mirror.&nbsp; The proprietary protection band from The Arora Report is very popular.&nbsp; The protection band puts all of the data, all of the indicators, all of the news, all of the crosscurrents, all of the models, and all of the analysis in an analytical framework that is easily actionable by investors.
Consider continuing to hold good, very long term, existing positions. Based on individual risk preference, consider a protection band consisting of cash or Treasury bills or short-term tactical trades as well as short to medium term hedges and short term hedges. This is a good way to protect yourself and participate in the upside at the same time.
You can determine your protection bands by adding cash to hedges.&nbsp; The high band of the protection is appropriate for those who are older or conservative. The low band of the protection is appropriate for those who are younger or aggressive.&nbsp; If you do not hedge, the total cash level should be more than stated above but significantly less than cash plus hedges.
A protection band of 0% would be very bullish and would indicate full investment with 0% in cash.&nbsp; A protection band of 100% would be very bearish and would indicate a need for aggressive protection with cash and hedges or aggressive short selling.
It is worth reminding that you cannot take advantage of new upcoming opportunities if you are not holding enough cash.&nbsp; When adjusting hedge levels, consider adjusting partial stop quantities for stock positions (non ETF); consider using wider stops on remaining quantities and also allowing more room for high beta stocks.&nbsp; High beta stocks are the ones that move more than the market.
<h4 class="wp-block-heading">Traditional 60/40 Portfolio</h4>
Probability based risk reward adjusted for inflation does not favor long duration strategic bond allocation at this time.
Those who want to stick to traditional 60% allocation to stocks and 40% to bonds may consider focusing on only high quality bonds and bonds of five year duration or less.&nbsp; Those willing to bring sophistication to their investing may consider using bond ETFs as tactical positions and not strategic positions at this time.
The Arora Report is known for its accurate calls. The Arora Report correctly called the big artificial intelligence rally before anyone else, the new bull market of 2023, the bear market of 2022, new stock market highs right after the virus low in 2020, the virus drop in 2020, the DJIA rally to 30,000 when it was trading at 16,000, the start of a mega bull market in 2009, and the financial crash of 2008. Please click here to sign up for a free forever <a href="https://thearorareport.com/generate-wealth-newsletter-benzinga">Generate Wealth Newsletter</a>.

Equities

Market Summary

Opinion

Markets

NVDA

Human-Like Reasoning AI Agents And Robots Are A Big Market For Nvidia, But Nvidia Stock Has A Problem

Insider Trades

Live On CNBC, Sarat Sethi Announces Sold APA

WIIM

TEAM

Atlassian shares are trading higher after Stephens & Co initiated coverage on the stock with an Equal-Weight rating and announced a $255 price target.

Wednesday, Immunovant,&nbsp;Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMVT#NASDAQ">IMVT</a>) released topline results from its Phase 3 study of batoclimab in myasthenia gravis (MG) and initial results from Period 1 of its Phase 2b study in chronic inflammatory <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">demyelinating polyneuropathy (CIDP)</a>.
Immunovant is a member of the&nbsp;Roivant Sciences Ltd.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROIV#NASDAQ">ROIV</a>) family of companies.
In the Phase 3 MG study, batoclimab met its primary endpoint of mean change from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) score in acetylcholine receptor <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44395056/immunovant-announces-positive-results-for-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory" rel="noreferrer noopener">antibody positive (AChR+) participants</a>.
<ul>
<li>Participants entering the study and randomized to 680mg of batoclimab given weekly by subcutaneous injection achieved a 5.6-point improvement (with 74% mean IgG reduction) in MG-ADL at Week 12.</li>
<li>In comparison, those randomized to 340mg of batoclimab given weekly by subcutaneous injection achieved a 4.7-point improvement (with 64% mean IgG reduction).</li>
<li>Those randomized to placebo experienced a 3.6-point improvement in MG-ADL at Week 12.</li>
</ul>
Initial batoclimab data in 73 patients pooled across all cohorts for the run-in Period 1 of the Phase 2b CIDP study demonstrated a 1.8 point improvement in aINCAT (compared to Period 1 baseline) at Week 12.
<ul>
<li>An 84% responder rate (with response defined as an aINCAT improvement ≥ 1) was observed among all patients whose IgG was reduced by ≥ 70%.</li>
<li>Other CIDP scales also demonstrated meaningful improvements for pooled batoclimab cohorts, with an improvement in I-RODS of 15.3, an improvement in MRC-SS of 5.6, and an improvement in grip strength of 15.1.</li>
</ul>
Safety and tolerability were observed to be consistent with prior batoclimab studies.
Immunovant does not intend to seek regulatory approval for batoclimab in MG or CIDP and is focused on leveraging data and learnings from the batoclimab studies to accelerate programs with IMVT-1402.
Immunovant plans to initiate potentially registrational studies in MG and CIDP with lead asset IMVT-1402 and has received clearance for its Investigational New Drug applications.
Immunovant will wait to decide on regulatory submissions for batoclimab until the results of the ongoing Phase 3 studies of batoclimab in thyroid eye disease are available.
Price Action: IMVT stock is down 0.40% at $18.72 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/03/44396557/spectral-ai-deepview-system-performs-plans-product-launch-in-2026" target="_blank" rel="noreferrer noopener">Spectral AI DeepView System Performs, Plans Product Launch In 2026</a></li>
</ul>

Biotech

Health Care

General

IMVT

ROIV

Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data

Regenxbio Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGNX#NASDAQ">RGNX</a>) revealed on Wednesday new interim data from two additional patients in the Phase 1/2 portion of the AFFINITY DUCHENNE trial of RGX-202, an investigational gene therapy for <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">Duchenne muscular dystrophy</a>.
Results were presented at the 2025 Muscular Dystrophy Association (MDA) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44397327/regenxbio-reports-positive-biomarker-data-from-affinity-duchenne-trial-of-rgx-202-gene-therapy" rel="noreferrer noopener">Clinical &amp; Scientific Conference</a>.
At dosing, microdystrophin expression was 122.3% higher in a patient age three compared to the control.
In a patient age seven, RGX-202 microdystrophin expression was 31.5% higher than in the control.
In all patients, RGX-202 was appropriately localized to the sarcolemma, demonstrating the differentiated construct with the CT-Domain is appropriately targeting the muscle.
RGX-202 microdystrophin expression results in ambulatory patients age eight and above are the highest reported microdystrophin levels across approved or investigational gene therapies.
To support a Biologics License Application (BLA) using the accelerated approval pathway, the primary endpoint in the pivotal phase of AFFINITY DUCHENNE is the proportion of participants whose RGX-202 microdystrophin expression is ≥10% at Week 12.
RGX-202 also demonstrates the highest reported vector genome copies (4.9-55.4) measured by qPCR across approved or investigational gene therapies.
As of Feb. 21, 2025, RGX-202 was well tolerated, with no serious adverse events or AEs of special interest. Common drug-related AEs included nausea, vomiting and fatigue. All were resolved and typically anticipated with gene therapy administration.
Phase 3 portion of the AFFINITY DUCHENNE trial is enrolling ambulatory patients (who can walk) aged one and above, on track for BLA submission in mid-2026.
Last week, Regenxbio reported a fourth-quarter loss of $1.01 per share, beating the consensus of $1.15.
Sales decreased slightly from $22.2 million to $21.21 million, missing the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $23.75 million</a>.
Regenxbio expects its cash, cash equivalents and marketable securities of $244.9 million as of Dec. 31, 2024, and the $110 million upfront payment to be received under the Nippon Shinyaku collaboration to fund its operations into the <a href="https://www.benzinga.com/pressreleases/25/03/n44315595/regenxbio-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-operational-updat" target="_blank" rel="noreferrer noopener">second half of 2026</a>.
RGNX Price Action: Regenxbio stock is up 5.90% at $8.26 at publication Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/03/44394817/exclusive-telomir-pharmaceuticals-lead-drug-candidate-inhibits-tumor-growth-in-aggressive-prostate-cancer-cells-animal-study-shows" target="_blank" rel="noreferrer noopener">Telomir Pharmaceuticals Lead Drug Candidate Inhibits Tumor Growth In Aggressive Prostate Cancer Cells, Animal Study Shows</a></li>
</ul>

Movers

RGNX

Regenxbio Touts Positive Biomarker Data From Duchenne Muscular Dystrophy Gene Therapy Trial

On Wednesday, Plug Power, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) announced the pricing of its underwritten registered offering, which includes 46.5 million shares of common stock and pre-funded warrants to purchase approximately 139 million shares, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44397534/plug-power-inc-announces-pricing-of-upsized-280-million-underwritten-offering" rel="noreferrer noopener">totaling 185.4 million common stock equivalents.</a>
The common stock equivalents will be accompanied by a total of 185.4 million warrants. The gross proceeds from this offering are expected to be about $280 million, before deducting underwriting fees and other expenses.
Each common stock share and accompanying warrant are being sold at a combined price of $1.51, while pre-funded warrants are priced at $1.509 with an exercise price of $0.001 per share.
The warrants have an exercise price of $2.00 per share and will become exercisable six months after issuance. Plug Power intends to use the net proceeds for working capital and general corporate purposes.
Also Read: <a target="_blank" href="http://benzinga.com/analyst-ratings/analyst-color/25/03/44399554/analysts-see-upside-for-95-of-sp-500-stocks-how-nvidia-tesla-stack-up" rel="noreferrer noopener">Analysts See Upside For 95% Of S&amp;P 500 Stocks: How Nvidia, Tesla Stack Up</a>
CEO Andy Marsh expressed that the funding would strengthen the company's financial position and help drive profitability in 2025.
The funds will support the company's initiatives to optimize operations, improve cash flow, and focus on sustainable growth. The offering is expected to close on or about March 20, 2025, subject to customary closing conditions.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, PLUG stock has lost over 50% in the past year. Investors can gain exposure to the stock via Global X Hydrogen ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYDR#NASDAQ">HYDR</a>) and&nbsp;ETF Series Solutions Defiance Next Gen H2 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HDRO#NYSE">HDRO</a>).
Recently, the company reported fourth-quarter revenue of&nbsp;$191.5 million, missing&nbsp;<a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">analyst&nbsp;estimates&nbsp;of&nbsp;$263.2 million</a>.
The company reached a pivotal milestone in electrolyzer deployments, expanded its hydrogen network, and enhanced the utilization of its manufacturing facilities.
Price Action: PLUG shares are trading lower by 0.93% to $1.605 at last check Wednesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/03/44401134/hutchmeds-oncology-revenue-hits-271-5-million-rising-65-on-fruzaqla-strength" target="_blank" rel="noreferrer noopener">Hutchmed&#8217;s Oncology Revenue Hits $271.5 Million, Rising 65% On Fruzaqla Strength</a></li>
</ul>
Photo via Shutterstock.

Offerings

ETF Series Solutions Defiance Next Gen H2 ETF

HDRO

HYDR

PLUG

What's Going On With Plug Power Stock Today?

Truist Securities analyst Michael Lewis maintains National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) with a Hold and raises the price target from $70 to $76.

Price Target

Analyst Ratings

Truist Securities Maintains Hold on National Health Investors, Raises Price Target to $76

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Immunovant (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMVT#NASDAQ">IMVT</a>) with a Buy and maintains $51 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Immunovant, Maintains $51 Price Target

Morgan Stanley analyst Andrew Tsai maintains KE Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEKE#NYSE">BEKE</a>) with a Overweight and raises the price target from $19 to $27.

BEKE

Morgan Stanley Maintains Overweight on KE Holdings, Raises Price Target to $27

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates ATAI Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) with a Buy and maintains $10 price target.

ATAI

HC Wainwright & Co. Reiterates Buy on ATAI Life Sciences, Maintains $10 Price Target

United Rentals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/URI#NYSE">URI</a>) short percent of float has risen 4.45% since its last report. The company recently reported that it has 1.75 million shares sold short, which is 3.05% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.16 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>United Rentals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742401826_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for United Rentals has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing United Rentals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, United Rentals's peer group average for short interest as a percentage of float is 4.99%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

What Does the Market Think About United Rentals?

Toyota Motor's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TM#NYSE">TM</a>) short percent of float has fallen 22.22% since its last report. The company recently reported that it has 921 thousand shares sold short, which is 0.07% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Toyota Motor Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742401820_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Toyota Motor has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Toyota Motor's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Toyota Motor's peer group average for short interest as a percentage of float is 5.86%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

What Does the Market Think About Toyota Motor?

Nu Holdings's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NU#NYSE">NU</a>) short percent of float has risen 13.04% since its last report. The company recently reported that it has 136.00 million shares sold short, which is 3.64% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.66 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Nu Holdings Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742401815_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Nu Holdings has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Nu Holdings's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Nu Holdings's peer group average for short interest as a percentage of float is 1.03%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Nu Holdings?

Ford Motor Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) shares are trading higher today.
On Wednesday, the company renewed its partnership with Churchill Downs Racetrack as the exclusive automotive partner of the Kentucky <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44398200/ford-named-exclusive-automotive-partner-of-the-kentucky-derby-in-multi-year-partnership-extension" rel="noreferrer noopener">Derby presented by Woodford Reserve</a>.
Under the multi-year deal extending through 2029, Ford will expand its presence at Churchill Downs by securing naming rights to the First Turn Club, now officially the Ford First Turn Club.
This extended collaboration grants Ford category exclusivity and an expanded presence with interactive vehicle displays to enhance fan engagement during Derby Week and beyond.
Related Read: <a target="_blank" href="https://www.benzinga.com//node/44390358" rel="noreferrer noopener">Elon Musk Calls It &#8216;Extreme Domestic Terrorism&#8217; After Website Publishes Data On US Tesla Owners</a>
Additionally, Ford will showcase exclusive luxury vehicle displays and new Ford-themed fan experiences at key locations, including the Paddock Plaza and VIP Gate, ensuring strong brand visibility throughout Derby Week.
Ford will continue its sponsorship of key Kentucky Derby and Oaks activations, including branding on the Derby Starting Gate, presenting sponsorship of the Churchill Downs Barn Area, a Derby Day race entitlement, exclusive digital content, and year-round vehicle displays at Churchill Downs.
Phil O&#8217;Connor, director of global marketing communications – Ford Blue and Model e at Ford Motor Company said, &#8220;Ford&nbsp;has a deep connection with the&nbsp;Louisville&nbsp;community. Our&nbsp;Louisville-based manufacturing facilities employ roughly 12,000 Kentuckians.&#8221;
&#8221;Our heritage of capability, passion and innovation make our friends at Churchill Downs Racetrack ideal partners. We&#8217;re excited for this next chapter in our partnership and honored to continue supporting the bluegrass state.&#8221;
Earlier this month, Ford Pro partnered with Work Truck Solutions to introduce an online tool that helps customers easily find road- and work-ready trucks <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44149002/work-truck-solutions-announces-collaboration-with-ford-pro-to-power-commercial-vehicle-locator" rel="noreferrer noopener">and vans in Ford dealer inventory</a>.
Investors can gain exposure to the stock via&nbsp;First Trust Nasdaq Transportation ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXR#NASDAQ">FTXR</a>).
Price Action: F shares are up 0.91% at $10.05 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/econ-s/25/03/44262286/tariff-uncertainty-poses-major-risk-to-us-automakers-how-much-could-ford-gm-earnings-fall" target="_blank" rel="noreferrer noopener">Tariff Uncertainty Poses Major Risk To US Automakers: How Much Could Ford, GM Earnings Fall?</a></li>
</ul>
Photo via Shutterstock.

Large Cap

Contracts

FTXR

Ford Renews Exclusive Partnership with Kentucky Derby, Expands Brand Presence Through 2029

INTC

Intel shares are trading lower, pulling back after gaining recently on new CEO optimism.

NVIDIA shares are trading higher amid the company's GTC Conference this week.

GILD

Gilead Sciences shares are trading lower after reports indicating the Trump administration is considering cuts to domestic HIV prevention programs.

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Precision BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTIL#NASDAQ">DTIL</a>) with a Buy and maintains $60 price target.

DTIL

HC Wainwright & Co. Reiterates Buy on Precision BioSciences, Maintains $60 Price Target

Press Releases

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA

Liquidia Corporation to Report Third Quarter 2024 Financial Results on November 11, 2024

Liquidia Corporation to Report Third Quarter 2024 Financial Results on November 13, 2024

Liquidia to Present at the Stifel 2024 Healthcare Conference

Earnings

Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Liquidia Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference

Management

Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors

Liquidia Corporation to Report Full Year 2024 Financial Results on March 19, 2025

Financing

Liquidia Corporation Strengthens Financial Position by Amending HealthCare Royalty Agreement to Incrementally Add Up to $100 Million

Liquidia Corporation Reports Full Year 2024 Financial Results and Provides Corporate Update

Comments

Liquidia

Noticias

Últimas noticias sobre Liquidia (NASDAQ:LQDA) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL